drugset / Trial / NCT03696186
Selective Treatment According to Molecular Subtype of Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal phenotype), group 2 (Neuroendocrine phenotype) or group 3 (Atypical phenotype) and a random assignment will be performed to standard or experimental treatment.
Timeline
- Start
- 2018-08-01
- Primary completion
- 2022-08
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | — |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Goserelin | Other / unclassified | 3.75 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |